A new trading day began on Friday, with TransCode Therapeutics Inc (NASDAQ: RNAZ) stock price up 6.64% from the previous day of trading, before settling in for the closing price of $0.25. RNAZ’s price has ranged from $0.22 to $128.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 98.02%. With a float of $17.23 million, this company’s outstanding shares have now reached $17.27 million.
Let’s determine the extent of company efficiency that accounts for 10 employees. In terms of profitability, gross margin is 25.19%, operating margin of -2367.04%, and the pretax margin is -2377.38%.
TransCode Therapeutics Inc (RNAZ) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of TransCode Therapeutics Inc is 0.19%, while institutional ownership is 11.46%. The most recent insider transaction that took place on Sep 28 ’23, was worth 25,168. In this transaction Chief Financial Officer of this company bought 49,350 shares at a rate of $0.51, taking the stock ownership to the 56,318 shares. Before that another transaction happened on Sep 28 ’23, when Company’s Chief Executive Officer bought 98,000 for $0.51, making the entire transaction worth $49,980. This insider now owns 180,262 shares in total.
TransCode Therapeutics Inc (RNAZ) Earnings and Forecasts
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -67.2 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.16 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 98.02% per share during the next fiscal year.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Trading Performance Indicators
Here are TransCode Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -75.05, a number that is poised to hit -0.74 in the next quarter and is forecasted to reach -0.47 in one year’s time.
Technical Analysis of TransCode Therapeutics Inc (RNAZ)
Looking closely at TransCode Therapeutics Inc (NASDAQ: RNAZ), its last 5-days average volume was 0.67 million, which is a drop from its year-to-date volume of 1.07 million. As of the previous 9 days, the stock’s Stochastic%D was 53.61%. Additionally, its Average True Range was 0.06.
During the past 100 days, TransCode Therapeutics Inc’s (RNAZ) raw stochastic average was set at 2.82%, which indicates a significant decrease from 64.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.11% in the past 14 days, which was lower than the 256.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.7209, while its 200-day Moving Average is $2.9173. However, in the short run, TransCode Therapeutics Inc’s stock first resistance to watch stands at $0.2799. Second resistance stands at $0.2931. The third major resistance level sits at $0.3123. If the price goes on to break the first support level at $0.2475, it is likely to go to the next support level at $0.2283. Should the price break the second support level, the third support level stands at $0.2151.
TransCode Therapeutics Inc (NASDAQ: RNAZ) Key Stats
With a market capitalization of 4.60 million, the company has a total of 6,622K Shares Outstanding. Currently, annual sales are 0 K while annual income is -18,550 K. The company’s previous quarter sales were 0 K while its latest quarter income was -3,330 K.
